Alloreactive t cells and cytokines in murine graft versus host disease 5

____________________________________________________________ References

CHAPTER 5 REFERENCES

Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster
J, Xu Y, Nooyen P, McClanahan T, Bacon KB, Figdor CG. 1997. A dendritic-cellderived C-C chemokine that preferentially attracts naive T cells. Nature. 387(6634):
713-717.
Allen RD, Staley TA and Sidman CL. 1993. Differential cytokine expression in
acute and chronic murine graft-versus-host disease. Eur. J. Immunol. 23: 333-337.
Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell
JI, McMichael AJ, Davis MM. 1996. Phenotypic analysis of antigen-specific T
lymphocytes. Science. 274(5284): 94-96.
Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C,
Heslop HE, Molldrem JJ, Rooney CM, Brenner MK. 2003. Selective depletion of
donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood.
102(6):2292-2299.
Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ,
Doney K, Martin, PJ, Nash R, Storb R. 1994. Treatment of acute graft-versus-host
disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.
Blood. 84: 1320-1324.
Anasetti C, Howe C, Petersdorf EW, Martin PJ, Hansen JA. 1994. Marrow
transplants from HLA matched unrelated donors: an NMDP update and the Seattle
experience. Bone Marrow Transplant. 13(6): 693-695.
Angulo R and Fulcher DA. 1998. Measurement of Candida-specific blastogenesis:
Comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine
incorporation, and CD69 expression. Cytometry. 34:143.

Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A,
Bandeira A. 2001. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T
cells through the production of IL-10. J Immunol. 166: 3008 –3018.
Armitage JO. 1994. Bone marrow transplantation. N Engl J Med. 330: 827-838.

Arnold D, Wasem C, Juillard P, Graber P, Cima I, Frutschi C, Herren S, Jakob
S, Alouani S, Mueller C, Chvatchko Y, Brunner T. 2002. IL-18-independent
cytotoxic T lymphocyte activation and IFN-gamma production during experimental
acute graft-versus-host disease. Int Immunol. 14(5): 503-511.
Asano M, Toda M, Sakaguchi N, Sakaguchi S. 1996. Autoimmune disease as a
consequence of developmental abnormality of a T cell subpopulation. J Exp Med.
184: 387 –396.

162


____________________________________________________________ References
Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. 1999. An essential role
for interleukin 10 in the function of regulatory T cells that inhibit intestinal
inflammation. J Exp Med. 190(7): 995-1004.
Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, Renz H,
Hallmann R, Scheffold A, Radbruch A, Hamann A. 1997. P- and E-selectin
mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues.
Nature. 385(6611): 81-83.
Aususel FM, Brent R, Kingston RE, Moore D. Preparation of cytoplasmic RNA
from tissue culture cells. Current Protocols in Molecular Biology. Wiley and Sons,
Singapore. Unit 4.1.5 (Supplement 1).
Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei
T, Martelli MP, Gambelunghe C. 1994. Successful engraftment of T-cell-depleted
haploidentical "three-loci" incompatible transplants in leukemia patients by addition
of recombinant human granulocyte colony-stimulating factor-mobilized peripheral
blood progenitor cells to bone marrow inoculum. Blood. 84(11): 3948-3955.
Baba M, Imai T, Nishimura M, Kakizaki M, Takagi S, Hieshima K, Nomiyama
H, Yoshie O. 1997. Identification of CCR6, the specific receptor for a novel
lymphocyte-directed CC chemokine LARC. J Biol Chem. 272(23): 14893-14898.

Baccarini M, Schwinzer R, Lohmann-Matthes ML. 1989. Effect of human
recombinant IL-2 on murine macrophage precursors. Involvement of a receptor
distinct from the p55 (Tac) protein. J Immunol. 142:118-125.
Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. 2001. CD4+CD25
regulatory T cells in human peripheral blood. J Immunol. 167: 1245 –1253.
Baecher-Allan C, Viglietta V and Hafler DA. 2002. Inhibition of human
CD4+CD25+ high regulatory T cell function. J Immunol. 169: 6210 –6217.
Baggiolini M. 1998. Chemokines and leukocyte traffic. Nature. 392: 565-568.
Bagot M, Cordonnier C, Tilkin AF, Heslan M, Vernant JP, Dubertret L, Levy
JP. 1986. A possible predictive test for graft-versus-host disease in bone marrow graft
recipients: the mixed-epidermal cell-lymphocyte reaction. Transplantation. 41(3):
316-319.
Bagot M, Mary JY, Heslan M, Kuentz M, Cordonnier C, Vernant JP, Dubertret
L, Levy JP. 1988. The mixed epidermal cell lymphocyte-reaction is the most
predictive factor of acute graft-versus-host disease in bone marrow graft recipients. Br
J Haematol. 70(4): 403-409.
Bargatze RF, Butcher EC. 1993. Rapid G protein-regulated activation event
involved in lymphocyte binding to high endothelial venules. J Exp Med. 178(1): 367372.

163


____________________________________________________________ References
Barrat FJ, Cua DJ and Boonstra A. 2002. In vitro generation of interleukin 10producing regulatory CD4+ T Cells is induced by immunosuppressive drugs and
inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 195: 603
–616.
Barrett AJ. 1989. Graft versus host disease--clinical features and biology. Bone
Marrow Transplant. 4 Suppl 4: 18-21.
Barrett AJ. 1997. Mechanisms of the graft-versus-leukemia reaction. Stem Cells. 15:
248-258.

Batra JK, FitzGerald DJ, Chaudhary VK, Pastan I. 1991. Single-chain
immunotoxins directed at the human transferrin receptor containing Pseudomonas
exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti- TFR(Fv). Mol.
Cell. Biol. 11, 2200.
Bell EB, Sparshott SM, Drayson MT, Ford WL. 1987. The stable and permanent
expansion of functional T lymphocytes in athymic nude rats after a single injection of
mature T cells J. Immunol. 139: 1379-1384.
Belperio JA, Burdick MD, Keane MP, Xue YY, Lynch JP 3rd, Daugherty BL,
Kunkel SL, Strieter RM. 2000. The role of the CC chemokine, RANTES, in acute
lung allograft rejection. J Immunol. 165(1): 461-472.
Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK,
Picker LJ, Butcher EC. 1991. The cutaneous lymphocyte antigen is a skin
lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte
adhesion molecule 1. J Exp Med. 174(6): 1461-1466.
Bishara A, Brautbar C, Nagler A, Slavin S, Leshem B, Cohen I, Kedar E. 1994.
Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease
and graft rejection after allogeneic bone marrow transplantation. Transplantation.
57(10): 1474-1479.
Bishop DK and Orosz CG. 1989. Limiting dilution analysis for alloreactive, TCGFsecretory T cells: two related LDA methods that discriminate between unstimulated
precursor T cells and in vivo-alloactivated T cells. Transplantation 47: 671-677.
Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC.
1987. The foreign antigen binding site and T cell recognition regions of class I
histocompatibility antigens. Nature. 329(6139): 512-518.
Bleul CC, Schultze JL and Springer TA. 1998. B lymphocyte chemotaxis regulated
in association with microanatomic localization, differentiation state, and B cell
receptor engagement. J Exp Med. 187(5): 753-762.
Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. 1997. The HIV coreceptors
CXCR4 and CCR5 are differentially expressed and regulated on human T
lymphocytes. Proc Natl Acad Sci U S A. 94(5): 1925-1930.

164


____________________________________________________________ References
Boehm U, Klamp T, Groot M, Howard JC. 1997. Cellular responses to interferongamma. Annu Rev Immunol. 15: 749-795. Review.
Boltard C, Tinsil J, Assan R, Mogenet A, Debussche X and Bach JF. 1992.
Treatment of type I diabetesmellitus with DAB486-IL-2, a toxin conjugate with
targets activated T-lymphocytes. Proceedings of the European Association for Study
of Diabetes, A218 (Abstract).
Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A,
Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. 1998. Differential
expression of chemokine receptors and chemotactic responsiveness of type 1 T helper
cells (Th1s) and Th2s. J Exp Med. 187(1): 129-134.
Borges E, Tietz W, Steegmaier M, Moll T, Hallmann R, Hamann A, Vestweber
D. 1997. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper
2 cells binds to P-selectin and supports migration into inflamed skin. J Exp Med.
185(3): 573-578.
Bouma GJ, van der Meer-prins EM, van der Woude FJ, van Rood JJ, Claas FH.
1995. Relevance of pretransplant donor-specific T cell allorepertoire for human
kidney graft survival. Transplantation. 59: 969-976.
Bowers WE. 1974. Graft-versus-host and cytotoxic activity of rat thoracic duct
lymphocytes fractionated by zonal centrifugation after culture on allogeneic
fibroblasts. J Immunol. 113(4): 1252-1261.
Bradley LM and Watson SR. 1996. Lymphocyte migration into tissue: the paradigm
derived from CD4 subsets. Curr Opin Immunol. 8(3): 312-320.
Brok HP, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. 1993. Interferon-γ
prevents graft-versus-host disease after allogeneic bone marrow transplantation in
mice. J. Immunol. 151: 6451-6459.
Bunjes D, Theobald M, Hertenstein B, Wiesneth M, Novotny J, Arnold R,
Heimpel H. 1995a. Successful therapy with donor buffy coat transfusions in patients

with relapsed chronic myeloid leukemia after bone marrow transplantation is
associated with high frequencies of host-reactive interleukin 2-secreting T helper
cells. Bone Marrow Transplant. 15(5): 713-719.
Bunjes D, Theobald M, Nierle T, Arnold R, Heimpel H. 1995b. Presence of hostspecific interleukin 2-secreting T helper cell precursors correlates closely with active
primary and secondary chronic graft-versus-host disease. Bone Marrow Transplant.
15(5): 727-732.
Burgstahler R, Kempkes B, Steube K, Lipp M. 1995. Expression of the chemokine
receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear
antigen 2. Biochem Biophys Res Commun. 215(2): 737-743.

165


____________________________________________________________ References
Butcher EC and Picker LJ. 1996. Lymphocyte homing and homeostasis. Science.
272(5258): 60-66.
Cacalano G, Lee J, Kikly K, Ryan AM, Pitts-Meek S, Hultgren B, Wood WI,
Moore MW. 1994. Neutrophil and B cell expansion in mice that lack the murine IL-8
receptor homolog. Science. 265(5172): 682-684. Erratum in: Science 1995.
270(5235):365.
Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. 1998.
Chemokines and the arrest of lymphocytes rolling under flow conditions. Science.
279(5349): 381-384.
Cantrell DA and Smith KA. 1983. Transient expression of interleukin 2 receptors.
Consequences for T cell growth. J Exp Med. 158: 1895-1911.
Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J.
2003. Regulatory T cells selectively express toll-like receptors and are activated by
lipopolysaccharide. J Exp Med. 197: 403 –411.
Cavazzana-Calvo M, Fromont C, Le Deist F, Lusardi M, Coulombel L, Derocq
JM, Gerota I, Griscelli C, Fischer A. 1990. Specific elimination of alloreactive T

cells by an anti-interleukin-2 receptor B chain-specific immunotoxin.
Transplantation. 50(1): 1-7.
Cavazzana-Calvo M, Stephan JL, Sarnacki S, Chevret S, Fromont C, de Coene
C, Le Deist F, Guy-Grand D, Fischer A. 1994. Attenuation of graft-versus-host
disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells
in an H-2 haplotype disparate mouse combination. Blood. 83(1): 288-298.
Cederbom L, Hall H and Ivars F. 2000. CD4+CD25+ regulatory T cells downregulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 30:
1538 –1543.
Ceredig R, Lowenthal JW, Nabholz M, Macdonald HR. 1985. Expression of
interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature.
314: 98-101.
Chadwick DE, Williams DP, Niho Y, Murphy JR. Minden MD. 1993.
Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony- stimulating factor
fusion protein on human leukemic blast cells. Leuk Lymphoma 11: 249.
Chan CH, Blazar BR, Eide CR, Kreitman RJ, Vallera DA. 1995. A murine
cytokine fusion toxin specifically targeting the murine granulocyte-macrophage
colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow
progenitor cells and GM-CSF-dependent tumor cells. Blood 86, 2732
Chao NJ, Schlegel PG. 1995. Prevention and treatment of graft-versus-host disease.
Ann N Y Acad Sci. 770: 130-140.

166


____________________________________________________________ References
Chaudhary VK, Gallo MG, FitzGerald DJ, Pastan I. 1990. A recombinant singlechain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria
toxin. Proc. Natl. Acad. Sci. U.S.A. 87, 9491.
Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan
I. 1989. A recombinant immunotoxin consisting of two antibody variable domains
fused to Pseudomonas exotoxin. Nature. 339: 394-397.

Chen BJ, Cui X, Liu C and Chao NJ. 2002. Prevention of graft-versus-host disease
while preserving graft-versus-leukemia effect after selective depletion of host-reactive
T cells by photodynamic cell purging process. Blood. 99: 3083-3088.
Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. 2002. CD4+CD25+
Immunoregulatory T cells: New therapeutics for Graft-vs-host disease. J Exp Med.
196: 401-406.
Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. 2002.
CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host
disease. J Exp Med. 196(3): 401-406.
Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies
O. 1995. Requirement of MIP-1 alpha for an inflammatory response to viral infection.
Science. 269(5230): 1583-1585.
Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM,
Ferrara JL. 1996. An experimental model of idiopathic pneumonia syndrome after
bone marrow transplantation: I. The roles of minor H antigens and endotoxin.
Blood. 88(8): 3230-3239.
Crabtree GR. 1989. Contingent genetic regulatory events in T lymphocyte
activation. Science. 243(4889): 355-361.
Dailey MO. 1998. Expression of T lymphocyte adhesion molecules: regulation during
antigen-induced T cell activation and differentiation. Crit Rev Immunol. 18(3): 153184.
Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. 1996. Interferon-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of
murine T helper 1 cells. Cell Immunol 173: 230–235.
De Gast GC, Gratama JW, Ringden O, Gluckman E. 1987. The multifactorial
etiology of graft-versus-host disease. Immunology Today. 8: 209-212.
De la Hera A, Toribio ML, Marquez C, Marcos MA, Cabrero E, Martinez-A C.
1986. Differentiation of human mature thymocytes: existence of a T3+4-8intermediate stage. Eur J Immunol. 16(6): 653-658.

167

____________________________________________________________ References
Delmonte L, O'Reilly RJ, Kirkpatrick D, Kapoor N. 1982. In vitro model for
detection of alloreactivity between HLA-matched donor-host pairs. Preliminary
evaluation as a predictor of graft-versus-host disease. Transplantation. 34(2): 100103.
Devos R, Plaetinck G, Cheroutre H, Simons G, Degrave W, Tavernier J, Remaut
E, Fiers W. 1983. Molecular cloning of human interleukin 2 cDNA and its expression
in E. coli. Nucleic Acids Res. 11(13): 4307-4323.
Dey BR, Yang YG, Szot GL, Pearson DA, Sykes M. 1998. Interleukin-12 inhibits
graft-versus-host disease through an Fas-mediated mechanism associated with
alterations in donor T-cell activation and expansion. Blood. 91(9): 3315-3322.
Dickinson AM, Sviland L, Dunn J, Carey P, Proctor SJ. 1991. Demonstration of
direct involvement of cytokines in graft-versus-host reactions using an in vitro human
skin explant model. Bone Marrow Transplant. 7(3): 209-216.
Dickinson AM, Sviland L, Hamilton PJ, Usher P, Taylor P, Jackson G, Dunn J,
Proctor SJ. 1994. Cytokine involvement in predicting clinical graft-versus-host
disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant.
13(1): 65-70.
Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. 2002. Human
CD4+CD25+ regulatory, contact-dependent T cells induce interleukin 10-producing,
contact-independent type 1-like regulatory T cells. J Exp Med. 196: 247 –253.
Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. 2001. Ex vivo
isolation and characterization of CD4+CD25+ T cells with regulatory properties from
human blood. J Exp Med. 193: 1303 –1310.
Dietrich PY, Caignard A, Lim A, Chung V, Pico JL, Pannetier C, Kourilsky P,
Hercend T, Even J, Triebel F. 1994. In vivo T-cell clonal amplification at time of
acute graft-versus-host disease. Blood. 84(8): 2815-2820.
Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M,
Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V.
2000. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients
with an active tumor-specific immune response. J Immunol. 165(11): 6644-6652.

Dunon D, Piali L, Imhof BA. 1996. To stick or not to stick: the new leukocyte
homing paradigm. Curr Opin Cell Biol. 8(5): 714-723.
Ebert LM and McColl SR. 2001. Coregulation of CXC chemokine receptor and
CD4 expression on T lymphocytes during allogeneic activation. J. Immunol. 166:
4870-4878.

168


____________________________________________________________ References
Engelhard D, Nagler A, Singer R, Barak V. 1994. Soluble interleukin-2 receptor
levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte
depleted bone marrow transplantation for hematological neoplasias. Leuk Lymphoma.
12(3-4): 273-280.
Ermann J, Szanya V, Ford GS, Paragas V, Fathman CG, Lejon K. 2001.
CD4+CD25+ T cells facilitate the induction of T cell anergy. J Immunol. 167: 4271 –
4275.
Farrar JJ, Benjamin WR, Hilfiker ML, Howard M, Farrar WL, Fuller-Farrar J.
1982. The biochemistry, biology, and role of interleukin 2 in the induction of
cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 63: 129-166.
Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR. 2000. Depletion of
alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow
Transplant. 2: S39-42.
Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. 2000b. Efficient
depletion of alloreactive donor T lymphocytes based on expression of two activationinduced antigens (CD25 and CD69). Br. J. Haematol. 109: 644-651.
Ferrara JL and Deeg HJ. 1991. Graft-versus-host disease. N. Engl. J. Med. 324:
667-674.
Filipovich AH, Vallera D, McGlave P, Polich D, Gajl-Peczalska K, Haake R,
Lasky L, Blazar B, Ramsay NK, Kersey J. 1990. T cell depletion with anti-CD5
immunotoxin in histocompatible bone marrow transplantation. The correlation

between residual CD5 negative T cells and subsequent graft-versus-host disease.
Transplantation. 50(3): 410-415.
Ford WL, Simmonds SJ and Atkins RC. 1975. Early cellular events in a systemic
graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor
lymphocytes which respond to each Ag-B-determined antigenic complex. J. Exp.
Med. 141: 681-696.
Frame JN, Collins NH, Cartagena T, Waldmann H, O'Reilly RJ, Dupont B,
Kernan NA. 1989. T cell depletion of human bone marrow. Comparison of Campath1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin
alone or in combination with sheep erythrocytes or immunomagnetic beads.
Transplantation. 47(6): 984-988.
Freitas AA and Rocha BB. 1993. Lymphocyte lifespans: homeostasis, selection and
competition. Immunol Today. 14(1): 25-29.
Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K,
Kakishita E. 2000. Elevated interleukin (IL)-18 levels during acute graft-versus-host
disease after allogeneic bone marrow transplantation. Br J Haematol. 109(3): 652657.

169


____________________________________________________________ References
Fujimori Y, Yoshimoto T, Matsui K, Tsutsui H, Okamoto T, Kashiwamura S,
Hada T, Okamura H, Kakishita E, Hara H, Nakanishi K. 2002. Increased
expression of interleukin-18 receptor on T lymphocytes in patients with acute graftversus-host disease after allogeneic bone marrow transplantation.
J Interferon Cytokine Res. 22(7): 751-754.
Fussell ST, Donnellan M, Cooley MA, Farrell C. 1994. Cytotoxic T lymphocyte
precursor frequency does not correlate with either the incidence or severity of graftversus-host disease after matched unrelated donor bone marrow transplantation.
Transplantation. 57(5): 673-676.
Gao W, Topham PS, King JA, Smiley ST, Csizmadia V, Lu B, Gerard CJ,
Hancock WW. 2000. Targeting of the chemokine receptor CCR1 suppresses
development of acute and chronic cardiac allograft rejection. J Clin Invest. 105(1):

35-44.
Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F, Gluckman E,
Andreeff M, Champlin RE. 1999. Effective depletion of alloreactive lymphocytes
from peripheral blood mononuclear cell preparations. Transplantation. 67: 124-130.
Garlisi CG, Pennline KJ, Smith SR, Siegel MI, Umland SP. 1993. Cytokine gene
expression in mice undergoing chronic graft-versus-host disease. Mol Immunol. 30(7):
669-677.
Garside P, Reid S, Steel M, Mowat AM. 1994. Differential cytokine production
associated with distinct phases of murine graft-versus-host reaction. Immunology.
82(2): 211-214.
Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P,
Trinchieri G, Sher A. 1994. Parasite-induced IL-12 stimulates early IFN-gamma
synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol.
153(6): 2533-2543.
Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L,
Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen H. 1997.
Caspase-1 processed IFN- -inducing factor and regulates LPS-induced IFNproduction. Nature 386: 617.
Ghayur T, Seemayer TA, Lapp WS. 1987. Kinetics of natural killer cell
cytotoxicity during the graft-versus-host reaction. Relationship between natural killer
cell activity, T and B cell activity, and development of histopathological alterations.
Transplantation. 44(2): 254-260.
Gillis S, Ferm MM, Ou W, Smith KA. 1978. T cell growth factor: parameters of
production and a quantitative microassay for activity. J Immunol. 120(6): 2027-2032.
Goldsmith MA and Greene WC. 1994. Interleukin-2 and the interleukin-2 receptor.
In: Thomson A. (ed.). The Cytokine Handbook (second edition). Pp. 58-80. Academic
Press, London.

170

____________________________________________________________ References
Gorczynski RM, Cohen Z, Fu XM, Hua Z, Sun Y, Chen Z. 1996. Interleukin-13,
in combination with anti-interleukin-12, increases graft prolongation after portal
venous immunization with cultured allogeneic bone marrow-derived dendritic cells.
Transplantation. 62(11): 1592-1600.
Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB,
Krueger JG. 1995. Response of psoriasis to a lymphocyte-selective toxin
(DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.
Nat Med. 1(5): 442-447.
Goulmy E, Stijnen T, Groenewoud AF, Persijn GG, Blokland E, Pool J, Paul LC,
van Rood JJ. 1989. Renal transplant patients monitored by the cell-mediated
lympholysis assay. Evaluation of its clinical value. Transplantation. 48:559-563.
Graca L, Thompson S, Lin C-Y, Adams E, Cobbold SP, Waldmann H. 2002.
Both CD4 +CD25+ and CD4+CD25- regulatory cells mediate dominant
transplantation tolerance. J Immunol. 168: 5558 –5565.
Grandea AG 3rd and Bevan MJ. 1992. Single-residue changes in class I major
histocompatibility complex molecules stimulate responses to self peptides. Proc Natl
Acad Sci U S A. 89(7): 2794-2798.
Green EA, Choi Y and Flavell RA. 2002. Pancreatic lymph node-derived
CD4+CD25+ Treg cells: highly potent regulators of diabetes that require TRANCERANK signals. Immunity. 16: 183 –191.
Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L.
2001. Regulatory T cells induced by 1α,25-dihydroxyvitamin D3 and mycophenolate
mofetil treatment mediate transplantation tolerance. J Immunol. 167: 1945 –1953.
Grone HJ, Weber C, Weber KS, Grone EF, Rabelink T, Klier CM, Wells TN,
Proudfood AE, Schlondorff D, Nelson PJ. 1999. Met-RANTES reduces vascular
and tubular damage during acute renal transplant rejection: Blocking monocyte arrest
and recruitment. FASEB J. 13: 1371-1383.
Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino
K, Okamura H, Nakanishi K. 1997. Activation of interferon- inducing factor
mediated by interleukin-1ß converting enzyme. Science 275: 206

Gullberg M and Smith KA. 1986. Regulation of T cell autocrine growth. T4+ cells
become refractory to interleukin 2. J Exp Med. 163(2): 270-284.
Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. 1998. A
chemokine expressed in lymphoid high endothelial venules promotes the adhesion
and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A. 95(1): 258-263.
Guy-Grand D and Vassalli P. 1987. Gut injury in mouse graft-versus-host reaction
(GVHR). Adv Exp Med Biol. 216A: 661-671.

171


____________________________________________________________ References
Habu S, Okumura K, Diamantstein T, Shevach EM. 1985. Expression of
interleukin 2 receptor on murine fetal thymocytes. Eur J Immunol. 15(5): 456-460.
Hahn HJ, Kuttler B, Dunger A, Kloting I, Lucke S, Volk HD, von Baehr R,
Diamantstein T. 1987. Prolongation of rat pancreatic islet allograft survival by
treatment of recipient rats with monoclonal anti-interleukin-2 receptor antibody and
cyclosporin. Diabetologia. 30(1): 44-46.
Hakim FT, Fowler DH, Shearer GM, Gress RE. 1998. Animal models of acute and
chronic graft-versus-host disease. Current Protocols in Immunology. S27: 4.3.14.3.21.
Hakim FT, Payne S, Shearer GM. 1994. Recovery of T cell populations after acute
graft-vs-host reaction. J Immunol. 152(1): 58-64.
Hall BM, Pearce NW, Gurley KE, Dorsch SE. 1990. Specific unresponsiveness in
rats with prolonged cardiac allograft survival after treatment with cyclosporine. III.
Further characterization of the CD4+ suppressor cell and its mechanisms of action.
J Exp Med. 171(1): 141-157.
Hall BM. 1991. Cells mediating allograft rejection. Transplantation. 51: 1141-1151.
Hancock WW, Gao W, Faia KL, Csizmadia V. 2000a. Chemokines and their
receptors in allograft rejection. Curr Opin Immunol. 12(5): 511-516.
Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M,

Gerard NP, Gerard C. 2000b. Requirement of the chemokine receptor CXCR3 for
acute allograft rejection. J Exp Med. 192(10): 1515-1520.
Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ,
Powrie F, Wood KJ. 2001. IL-10 is required for regulatory T cells to mediate
tolerance to alloantigens in vivo. J Immunol. 166(6):3789-96.
Harris DT, Sakiestewa D, Lyons C, Kreitman RJ, Pastan I. 1999. Prevention of
graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells
with recombinant toxins that target the interleukin 2 (IL-2) receptor. Bone Marrow
Transplant. 23: 137-144.
Hartwig UF, Robbers M, Wickenhauser C, Huber C. 2002. Murine acute graftversus-host disease can be prevented by depletion of alloreactive T lymphocytes using
activation-induced
cell
death.
Blood.
99(8):
3041-3049.
Hasegawa H, Utsunomiya Y, Yasukawa M, Yanagisawa K, Fujita S. 1994.
Induction of G protein-coupled peptide receptor EBI 1 by human herpesvirus 6 and 7
infection in CD4+ T cells. J Virol. 68(8): 5326-5329.
Hayry P. 1989. Mechanisms of rejection. Curr Opin Immunol. 1: 1230-1235.

172


____________________________________________________________ References
Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA,
Tary-Lehmann M. 1999. Pretransplant frequency of donor-specific, IFN-gammaproducing lymphocytes is a manifestation of immunologic memory and correlates
with the risk of posttransplant rejection episodes. J Immunol. 163(4): 2267-2275.
Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. 1993.
Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med.

177(5): 1505-1509.
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. 2002. Donor-type
CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease
after allogeneic bone marrow transplantation. J Exp Med. 196(3): 389-399.
Holda JH, Maier T and Claman HN. 1990. IL-3, IL-4, and IL-6 enhance IFNgamma-dependent bone marrow natural suppressor activity. Cell Immunol. 125(2):
459-468.
Hori S, Nomura T and Sakaguchi S. 2003. Control of regulatory T cell development
by the transcription factor FOXP3. Science. 1057 –1061.
Howard M, Matis L, Malek TR, Shevach E, Kell W, Cohen D, Nakanishi K, Paul
WE. 1983. Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I. J
Exp Med. 158(6): 2024-2039.
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. 1993.
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced
macrophages. Science. 260(5107): 547-549.
Hu H, Dong Y, Feng P, Fechner J, Hamawy M, Knechtle SJ. 2003. Effect of
immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein
diacetate succinimidyl ester labeling. Transplantation. 75: 1075-1077
Hu H, Robertus M, de Jonge N, Gmelig-Meyling FH, van der Meulen A,
Schuurman HJ, Doornewaard H, van Prooijen HC, de Weger RA. 1994.
Reduction of donor-specific cytotoxic T lymphocyte precursors in peripheral blood of
allografted heart recipients. Transplantation. 58: 1263-1268.
Hu HZ, de Jonge N, Doornewaard H, Gmelig-Meyling FH, Tilanus MG,
Bosboom K, Robertus M, Plomp S, van Reijsen FC, Laphor JR, Schuurman HJ,
Deweger RA. 1994. Cytotoxic T lymphocytes infiltrating the human cardiac allograft
show a restriction in T-cell receptor V beta gene usage: a study on serial biopsy and
blood specimens. J Heart Lung Transplant. 13: 1058-1071.
Hu H, Stavrou S, Cairns Baker B, Tornatore C, Scharff J, Okunieff P, Neville
DM Jr. 1997. Depletion of T lymphocytes with immunotoxin retards the progress of
experimental allergic encephalomyelitis in rhesus monkeys. Cell Immunol. 177(1):
26-34.

173


____________________________________________________________ References
Hu HZ, Li GL, Lim YK, Chan SH, Yap EH. 1999. Kinetics of interferon-γ
secretion and its regulatory factors in the early phase of acute graft-versus-host
disease. Immunology. 98: 379-385.
Hu HZ, New JY, Li B, Chan SH, Yap EH. 2000. Depletion of activated alloreactive
T cells in prevention of acute graft-versus-host disease. Transplant. Proc. 32: 24562457.
Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi
S. 1999. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic
and suppressive T cells as a key function of the thymus in maintaining immunologic
self-tolerance. J Immunol. 162(9): 5317-5326.
Itoi H, Fujimori Y, Tsutsui H, Matsui K, Futatsugi S, Okamura H, Hara H,
Hada T, Kakishita E, Nakanishi K. 2001. Fas ligand-induced caspase-1-dependent
accumulation of interleukin-18 in mice with acute graft-versus-host disease. Blood.
98(1): 235-237.
Jacobson LO, Simmons EL, Marks EK, Eldredge JH. 1951. Recovery from
radiation injury. Science. 113(2940): 510-511.
Jean LF and Murphy JR.1991. Diphtheria toxin receptor-binding domain
substitution with interleukin 6: Genetic construction and interleukin 6 receptorspecific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Eng.
4: 989.
Jelinek DF and Lipsky PE. 1987. Regulation of human B lymphocyte activation,
proliferation, and differentiation. Adv Immunol. 40: 1-59.
Johnsen HE, Beatty PG, Michelson E, Hansen JA, Thomas ED. 1992a. Donor
alloreactivity may predict acute graft-versus-host disease in HLA-matched bone
marrow transplantation for leukemia in early remission. Eur J Haematol. 48(5): 249253.
Johnsen HE, Bostrom L, Moller J, Jorgensen JA, Jensen L, Ringden O. 1992b. A
study of donor alloreactivity, which may predict acute graft-versus-host disease in

HLA identical bone marrow transplantations for early leukaemia. Scand J Immunol.
35(3): 353-360.
Johnsen HE, Mickelson E, Beatty PG, Hansen JA. 1992c. Donor alloreactivity may
predict acute graft-versus-host disease in patients receiving marrow transplants from
HLA identical siblings. Bone Marrow Transplant. 9(2): 91-96.
Jones G. 1973. The number of reactive cells in mouse lymphocyte cultures stimulated
by PHA, Con A or histocompatibility antigen. J. Immunol. 111: 914-920.

174


____________________________________________________________ References
Jones MS, Riley R, Hamilton BL, Paupe J, Perez D, Levy RB. 1994. Endogenous
superantigens in allogeneic bone marrow transplant recipients rapidly and selectively
expand donor T cells which can produce IFN-gamma. Bone Marrow Transplant.
14(5): 725-735.
Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. 2002.
Infectious tolerance: human CD25+ regulatory T cells convey suppressor activity to
conventional CD4+ T helper cells. J Exp Med. 196: 255 –260.
Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. 2000. Induction of interleukin
10-producing, non-proliferating CD4+ T cells with regulatory properties by repetitive
stimulation with allogeneic immature human dendritic cells. J Exp Med. 192: 1213 –
1222.
Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. 2001.
Identification and functional characterization of human CD4+CD25+ T cells with
regulatory properties isolated from peripheral blood. J Exp Med. 193: 1285 –1294.
Joshua T and Rubin MD. 1995. Interleukin-2: Its rationale and role in the treatment
of patients with cancer. In: Kurzrock R. (ed.). Cytokine: Interleukins and their
Receptors. Pp. 83-105. Kluwer Academic Publishers.
Kalifa C, Hartmann O, Demeocq F, Vassal G, Couanet D, Terrier-Lacombe MJ,

Valteau D, Brugieres L, Lemerle J. 1992. High-dose busulfan and thiotepa with
autologous bone marrow transplantation in childhood malignant brain tumors: a phase
II study. Bone Marrow Transplant. 9(4): 227-233.
Kaminski E, Hows J, Man S, Brookes P, Mackinnon S, Hughes T, Avakian O,
Goldman JM, Batchelor JR. 1989. Prediction of graft versus host disease by
frequency analysis of cytotoxic T cells after unrelated donor bone marrow
transplantation. Transplantation. 48(4): 608-613.
Kaminski E, Sharrock C, Hows J, Ritter M, Arthur C, McKinnon S, Batchelor
JR. 1988. Frequency analysis of cytotoxic T lymphocyte precursors--possible
relevance to HLA-matched unrelated donor bone marrow transplantation. Bone
Marrow Transplant. 3(2): 149-155.
Kapoor A, Morita K, Engeman TM, Koga S, Vapnek EM, Hobart MG, Fairchild
RL. 2000. Early expression of interferon-gamma inducible protein 10 and monokine
induced by interferon-gamma in cardiac allografts is mediated by CD8+ T cells.
Transplantation. 69(6): 1147-1155.
Kapoor A, Morita K, Engeman TM, Vapnek EM, Hobart M, Novick AC,
Fairchild RL. 2000. Intragraft expression of chemokine gene occurs early during
acute rejection of allogeneic cardiac grafts. Transplant Proc. 32(4): 793-795.

175


____________________________________________________________ References
Keever CA, Leong N, Cunningham I, Copelan EA, Avalos BR, Klein J, Kapoor
N, Adams PW, Orosz CG, Tutschka PJ. 1994. HLA-B44-directed cytotoxic T cells
associated with acute graft-versus-host disease following unrelated bone marrow
transplantation. Bone Marrow Transplant. 14(1): 137-145.
Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V,
Huelskamp AM, Davidson NE. 1994. Phase I trial of interferon gamma to potentiate
cyclosporine-induced graft-versus-host disease in women undergoing autologous

bone marrow transplantation for breast cancer. J Clin Oncol. 12(2): 249-257.
Kernan NA. 1994. T-cell depletion for prevention of graft-versus-host disease. In:
Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston,
MA: Blackwell;124-135.
Kingsley CI, Karim M, Bushell AR, Wood KJ. 2002. CD25+CD4+ regulatory T
cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of
alloresponses. J Immunol. 168: 1080 –1086.
Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. 1985.
Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs
cardiac allograft survival in mice. J Exp Med. 162(1): 358-362.
Koga S, Auerbach MB, Engeman TM, Novick AC, Toma H, Fairchild RL. 1999.
T cell infiltration into class II MHC-disparate allografts and acute rejection is
dependent on the IFN-γ-induced chemokine Mig. J. Immunol. 163: 4878-4885.
Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. 2002.
Alloantigen-specific T-cell depletion in a major histocompatibility complex fully
mismatched murine model provides effective graft-versus-host disease prophylaxis in
the presence of lymphoid engraftment. Br. J. Haematol. 118: 108-116.
Kondo T, Morita K, Watarai Y, Auerbach MB, Taub DD, Novick AC, Toma H,
Fairchild RL. 2000. Early increased chemokine expression and production in murine
allogeneic skin grafts is mediated by natural killer cells. Transplantation. 69(5): 969977.
Korngold R, Sprent J. 1987. T cell subsets and graft-versus-host disease.
Transplantation. 44(3): 335-339.
Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S. 2000.
Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and
phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol. 12(8):
1145-1155.
Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. 1986. Therapy with
monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents
or reverses acute allograft rejection in rats. Proc Natl Acad Sci U S A. 83(8): 26242627.

176


____________________________________________________________ References
Lakkis F, Steele A, Pacheco-Silva A, Rubin-Kelley V, Strom TB, Murphy JR.
1991. Interleukin 4 receptor targeted cytotoxicity: Genetic construction and in vivo
immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion
protein. Eur J Immunol. 21: 2253.
Lambert P, Falmagne P, Capiau C, Zanen J, Ruysschaert JM, Dirkx J. 1980.
Primary structure of diphtheria toxin fragment B: Structural similarities with lipid
binding domains. J Cell Biol. 87: 837.
Lan FS, Zeng DF, Higuchi M, Huie P, Higgins JP, Strober S. 2001. Predominance
of NK1.1+TCR+ or DX5+TCR+ T Cells in Mice Conditioned with Fractionated
Lymphoid Irradiation Protects Against Graft-Versus-Host Disease: "Natural
Suppressor" Cells. J. Immunol. 167: 2087 - 2096.
Leonard JP, Waldburger KE, Goldman SJ. 1995. Prevention of experimental
autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med.
181(1): 381-386.
Levings MK, Sangregorio R and Roncarolo M-G. 2001. Human CD25+CD4+ T
regulatory cells suppress naive and memory T cell proliferation and can be expanded
in vitro without loss of function. J Exp Med. 193: 1295 –1301.
Levings MK, Sangregorio R and Sartirana C. 2002. Human CD25+ CD4+ T
suppressor cell clones produce transforming growth factor b, but not interleukin 10,
and are distinct from type 1 T regulatory cells. J Exp Med. 196: 1335 –1346.
Li B, New JY, Yap EH, Lu JH, Chan SH, Hu HZ. 2001.Blocking L-selectin and
α4-integrin changes donor cell homing pattern and ameliorates murine acute graft
versus host disease. Eur. J. Immunol. 31: 617-624.
Li XC, Demirci G, Ferrari-Lacraz S, Groves C, Coyle A, Malek TR, Strom TB.
2001. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7: 114118.
Liu Z, Geboes K and Hellings P. 2001. B7 interactions with CD28 and CTLA-4

control tolerance or induction of mucosal inflammation in chronic experimental
colitis. J Immunol. 167: 1830 –1838.
Lloyd AR, Oppenheim JJ, Kelvin DJ, Taub DD. 1996. Chemokines regulate T cell
adherence to recombinant adhesion molecules and extracellular matrix proteins.
J Immunol. 156(3):932-938.
Lochner M and Forster I. 2002-2003. Anti-interleukin-18 therapy in murine models
of inflammatory bowel disease. Pathobiology. 70(3): 164-169. Review.
Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini
M, Moser B. 1996a. Chemokine receptor specific for IP10 and mig: structure,
function, and expression in activated T-lymphocytes. J Exp Med. 184(3): 963-969.

177


____________________________________________________________ References
Loetscher P, Seitz M, Baggiolini M, Moser B. 1996b. Interleukin-2 regulates CC
chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J
Exp Med. 184(2): 569-577.
Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C,
Dayer JM. 1998. CCR5 is characteristic of Th1 lymphocytes. Nature. 391(6665):
344-345.
Lombardi G, Sidhu S, Batchelor R, Lechler R. 1994. Anergic T cells as suppressor
cells in vitro. Science. 264: 1587 –1589.
Lorenz E, Uphoff D, Reid TR, Shelton E. 1951. Modification of irradiation injury in
mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 12(1): 197-201.
Lowenthal JW and Greene WC. 1987. Contrasting interleukin 2 binding properties
of the alpha (p55) and beta (p70) protein subunits of the human high-affinity
interleukin 2 receptor. J Exp Med. 166(4): 1156-1161.
Lu Y, Sakamaki S, Kuroda H, Kusakabe T, Konuma Y, Akiyama T, Fujimi A,
Takemoto N, Nishiie K, Matsunaga T, Hirayama Y, Kato J, Kon S, Kogawa K,

Niitsu Y. 2001. Prevention of lethal acute graft-versus-host disease in mice by oral
administration of T helper 1 inhibitor, TAK-603. Blood. 97: 1123-1130.
Lyons AB and Parish CR. 1994. Determination of lymphocyte division by flow
cytometry. J. Immunol. Meth. 171: 131-137.
Mackay CR. 1993. Homing of naive, memory and effector lymphocytes. Curr Opin
Immunol. 5(3): 423-427.
Malkovsky M, Loveland B, North M, Asherson GL, Gao L, Ward P, Fiers W.
1987. Recombinant interleukin-2 directly augments the cytotoxicity of human
monocytes. Nature. 325(6101): 262-265.
Maloy KJ and Powrie F. 2001. Regulatory T cells in the control of immune
pathology. Nat Immuno.l 2: 816 –822.
Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, Leblond V,
Michallet M, Dreyfus F, Ifrah N. 1987. Impact of T-cell depletion on outcome of
allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet.
2(8552): 175-178.
Marmont AM. 1994. Immune ablation followed by allogeneic or autologous bone
marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells.
12(1): 125-135.
Matesic D, Lehmann PV and Heeger PS. 1998. High-resolution characterization of
cytokine-producing alloreactivity in naive and allograft-primed mice.
Transplantation. 65: 906-914.

178


____________________________________________________________ References
Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. 1963.
Haematopoetic chimera in man after allogeneic (homologous) bone-marrow
transplantation. (control of the secondary syndrome. Specif tolerance due to the
chimerism). Br Med J. 5373: 1633-1635.

Maury S, Salomon B, Klatzmann D, Cohen JL. 2001. Division rate and phenotypic
differences discriminate alloreactive and nonalloreactive T cells transferred in lethally
irradiated mice. Blood. 98: 3156-3158.
Mavroudis DA, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman RJ, Pastan
I, Barrett AJ. 1996. Specific depletion of alloreactivity against haplotype
mismatched related individuals by a recombinant immunotoxin: a new approach to
graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation.
Bone Marrow Transplant. 17(5):793-799.
McHughRS, Whitters MJ, Piccirillo CA. 2002. CD4+CD25+ immunoregulatory T
cells: gene expression analysis reveals a functional role for the glucocorticoid-induced
TNF receptor. Immunity. 16: 311 –323.
Mercer-Jones MA, Shrotri MS, Heinzelmann M, Peyton JC, Cheadle WG. 1999.
Regulation of early peritoneal neutrophil migration by macrophage inflammatory
protein-2 and mast cells in experimental peritonitis. J. Leukoc. Biol. 65: 249-255.
Meuer SC, Hussey RE, Cantrell DA, Hodgdon JC, Schlossman SF, Smith KA,
Reinherz EL. 1984. Triggering of the T3-Ti antigen-receptor complex results in
clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway.
Proc Natl Acad Sci U S A. 81(5): 1509-1513.
Mickelson EM, Bartsch GE, Hansen JA, Dupont B. 1993. The MLC assay as a test
for HLA-D region compatibility between patients and unrelated donors: results of a
national marrow donor program involving multiple centers. Tissue Antigens. 42: 465472.
Mickelson EM, Longton G, Anasetti C, Petersdorf E, Martin P, Guthrie LA,
Hansen JA. 1996. Evaluation of the mixed lymphocyte culture (MLC) assay as a
method for selecting unrelated donors for marrow transplantation. Tissue Antigens.
47: 27-36.
Middlebrook JL, Dorland RB and Leppla SH. 1978. Association of diphtheria
toxin with Vero cells. J Biol Chem. 253: 7325.
Moreau P and Cesbron A. 1994. HLA-DP and allogeneic bone marrow
transplantation. Bone Marrow Transplant. 13(6): 675-681.
Moser B, Loetscher P. 2001. Lymphocyte traffic control by chemokines. Nat

Immunol. 2(2):123-128.
Mosmann TR and Sad S. 1996. The expanding universe of T-cell subsets: Th1, Th2
and more. Immunol Today. 17(3): 138-146.

179


____________________________________________________________ References
Mowat AM. 1989. Antibodies to IFN-gamma prevent immunologically mediated
intestinal damage in murine graft-versus-host reaction. Immunology. 68(1): 18-23.
Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B, Suzuki K,
Asakura H, Matsushima K. 1999. Active participation of CCR5(+)CD8(+) T
lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin
Invest. 104(1): 49-57.
Murphy JR and Strom TB. 1990. Diphtheria toxin-peptide hormone fusion proteins:
Protein engineering and selective action of a new class of recombinant biological
response modifiers. In: edited by Moss, J. and Vaughan, M. ADP-ribosylation Toxins
and G Proteins: Insights into Signal Transduction, American Society for
Microbiology, Washington, DC: 141-159.
Murphy JR and van der Spek JC. 1995. Targeting diphtheria toxin to growth factor
receptors. Semin. Cancer Biol. 6, 259.
Murphy JR, Bishai W, Borowski M, Miyanohara A, Boyd J, Nagle S. 1986.
Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria
toxin-related alpha-melanocyte- stimulating hormone fusion protein. Proc Natl Acad
Sci USA 83: 8258.
Nagler A, Ackerstein A, Barak V, Slavin S. 1994. Treatment of chronic
myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha
2a. J Hematother. 3(1): 75-82.
Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH. 2002.
Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte

reactivity to donor HLA-DR peptides: potential novel assay for prediction of
outcomes for renal transplant recipients. J Am Soc Nephrol. 13: 252-259.
Nakamura H, Komatsu K, Ayaki M, Kawamoto S, Murakami M, Uoshima N,
Yagi T, Hasegawa T, Yasumi M, Karasuno T, Teshima H, Hiraoka A, Masaoka
T. 2000. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in
patients with acute graft-versus-host disease after allogeneic bone marrow
transplantation. J Allergy Clin Immunol. 106(1 Pt 2): S45-50.
Nakarai T, Robertson MJ, Streuli M, Wu Z, Ciardelli TL, Smith KA, Ritz J.
1994. Interleukin 2 receptor gamma chain expression on resting and activated
lymphoid cells. J Exp Med. 180(1): 241-251.
Napolitano M, Zingoni A, Bernardini G, Spinetti G, Nista A, Storlazzi CT,
Rocchi M, Santoni A. 1996. Molecular cloning of TER1, a chemokine receptor-like
gene expressed by lymphoid tissues. J Immunol. 157(7): 2759-2763.
Nelson PJ and Krensky AM. 2001. Chemokines, chemokine receptors and allograft
rejection. Immunity. 14: 377-386.

180


____________________________________________________________ References
Neville DM, Jr, Srinivasachar K, Stone R, Scharff J. 1989. Enhancement of
immunotoxin efficacy by acidcleavable cross-linking agents utilizing diphtheria toxin
andtoxin mutants. J. Biol. Chem. 264, 14653.
New JY, LiB, Koh WP, Ng HK, Tan SY, Yap EH, Chan SH, Hu HZ. 2002. T cell
infiltration and chemokine expression: Relevance to the disease localization in murine
graft-versus-host disease. Bone Marrow Transplant. 29: 979-986.
Ng WF, Duggan PJ and Ponchel F. 2001. Human CD4+CD25+ cells: a naturally
occurring population of regulatory T cells. Blood. 98: 2736 –2744.
Ngo VN, Tang HL and Cyster JG. 1998. Epstein-Barr virus-induced molecule 1
ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly

attracts naive T cells and activated B cells. J Exp Med. 188(1): 181-191.
Nicholls PJ and Youle RJ. 1992. The Structure of diphtheria toxin as a guide to
rational design. In Genetically Engineered Toxins (A. E. Frankel, Ed.) pp 339-363,
Marcel Dekker Inc., New York.
Nicholls PJ, Johnson VG, Andrew SM, Hoogenboom HR., Raus JCM, Youle RJ.
1993. Characterization of single-chain antibody (sFv)-toxin fusion proteins produced
in vitro in rabbit reticulocyte lysate. J. Biol. Chem. 268, 5302.
Nicola NA. 1994. Cytokine pleiotropy and redundancy: a view from the receptor.
Stem Cells. 12 Suppl 1: 3-12; discussion 12-14.
Niederwieser D, Herold M, Woloszczuk W, Aulitzky W, Meister B, Tilg H, Gastl
G, Bowden R, Huber C. 1990. Endogenous IFN-gamma during human bone marrow
transplantation. Analysis of serum levels of interferon and interferon-dependent
secondary messages. Transplantation. 50(4): 620-625.
Nielsen HE. 1978. Quantitative aspects of in vitro lymphocyte culture. Dan. Med.
Bull. 25: 93-106.
Nierle T, Bunjes D, Arnold R, Heimpel H, Theobald M. 1993. Quantitative
assessment of posttransplant host-specific interleukin-2-secreting T-helper cell
precursors in patients with and without acute graft-versus-host disease after allogeneic
HLA-identical sibling bone marrow transplantation. Blood. 81(3): 841-848.
Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. 2000. Th1 and Th2 mediate
acute graft-versus-host disease, each with distinct end-organ targets. J. Clin. Invest.
105:1289-1298.
Ogata M, Lorberboum-Galski H, FitzGerald D, Pastan I. 1988. IL-2-PE40 is
cytotoxic for activated T lymphocytes expressing IL-2 receptors. J Immunol. 141(12):
4224-4228.
Ogg GS and McMichael AJ. 1998. HLA-peptide tetrameric complexes. Curr Opin
Immunol. 10(4): 393-396.

181

____________________________________________________________ References
Ohashi Y, Takeshita T, Nagata K, Mori S, Sugamura K. 1989. Differential
expression of the IL-2 receptor subunits, p55 and p75 on various populations of
primary peripheral blood mononuclear cells. J Immunol. 143(11): 3548-3555.
Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. 1998.
Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol.
10(3): 259-264. Review.
Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T,
Torigoe K, Okura T, Nukada Y, Hattori K. 1995. Cloning of a new cytokine that
induces IFN- production by T cells. Nature 378:88.
Ortaldo JR, Mason AT, Gerard JP, Henderson LE, Farrar W, Hopkins RF 3rd,
Herberman RB, Rabin H. 1984. Effects of natural and recombinant IL 2 on
regulation of IFN gamma production and natural killer activity: lack of involvement
of the Tac antigen for these immunoregulatory effects. J Immunol. 133(2): 779-783.
Pachynski RK, Wu SW, Gunn MD, Erle DJ. 1998. Secondary lymphoid-tissue
chemokine (SLC) stimulates integrin alpha 4 beta 7-mediated adhesion of
lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) under
flow. J Immunol. 161(2): 952-956.
Palathumpat V, Dejbakhsh-Jones S, Holm B, Strober S. 1992a. Different subsets
of T cells in the adult mouse bone marrow and spleen induce or suppress acute graftversus-host disease. J Immunol. 149(3): 808-817.
Palathumpat V, Holm B, Dejbakhsh-Jones S, Strober S. 1992b. Treatment of
BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow
and spleen cells. J Immunol. 148(10): 3319-3326.
Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi
MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN. 1994. Infusions of
donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders
after allogeneic bone marrow transplantation. N Engl J Med. 330(17):1185-1191.
Pasare C and Medzhitov R. 2003. Toll pathway-dependent blockade of CD4+CD25+
T cell-mediated suppression by dendritic cells. Science. 1033 –1036.

Paul WE and Seder RA. 1994. Lymphocyte responses and cytokines. Cell. 76(2):
241-251.
Pei J, Martin PJ, Longton G, Masewicz S, Mickelson E, Petersdorf E, Anasetti C,
Hansen J. 1997. Evaluation of pretransplant donor anti-recipient cytotoxic and helper
T lymphocyte responses as correlates of acute graft-vs.-host disease and survival after
unrelated marrow transplantation. Biol. Blood Marrow Transplant. 3: 142-149.
Piccirillo CA and Shevach EM. 2001. Control of CD8+ T cell activation by
CD4+CD25+ immunoregulatory cells. J Immunol. 167:137 –1140.

182


____________________________________________________________ References
Picker LJ and Butcher EC. 1992. Physiological and molecular mechanisms of
lymphocyte homing. Annu Rev Immunol. 10: 561-591.
Picker LJ. 1994. Control of lymphocyte homing. Curr Opin Immunol. 6(3): 394-406.
Pontoux C, Banz A and Papiernik M. 2002. Natural CD4 CD25+ regulatory T cells
control the burst of superantigen-induced cytokine production: the role of IL-10. Int
Immunol.14: 233 –239.
Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE,
Moser B, Mackay CR. 1998. The chemokine receptors CXCR3 and CCR5 mark
subsets of T cells associated with certain inflammatory reactions. J Clin Invest.
101(4): 746-754.
Ralph P, Nakoinz I and Rennick D. 1988. Role of interleukin 2, interleukin 4, and
alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent
tumoricidal activity. J Exp Med. 167(2): 712-717.
Raulet DH. 1985. Expression and function of interleukin-2 receptors on immature
thymocytes. Nature. 314(6006): 101-103.
Read S, Malmstrom V and Powrie F. 2000. Cytotoxic T lymphocyte-associated
antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells

that control intestinal inflammation. J Exp Med. 192(2): 295-302.
Reddy P, Teshima T, Kukuruga M, Ordemann R, Liu C, Lowler K, Ferrara JL.
2001. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fasmediated donor T cell apoptosis. J Exp Med. 194(10): 1433-1440.
Reinsmoen NL and Zeevi A. 2002. Evaluation of the cellular immune response in
transplan-tation. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical
Laboratory Immunology, 6th edn. Washington DC: American Society for
Microbiology Press: 1164–1175.
Reinsmoen NL. 2002. Cellular methods used to evaluate the immune response in
transplantation. Tissue Antigens. 59: 241-250.
Ringheim GE, Freimark BD and Robb RJ. 1991. Quantitative characterization of
the intrinsic ligand-binding affinity of the interleukin 2 receptor beta chain and its
modulation by the alpha chain and a second affinity-modulating element. Lymphokine
Cytokine Res. 10(3): 219-224.
Robb RJ, Kutny RM and Chowdhry V. 1983. Purification and partial sequence
analysis of human T-cell growth factor. Proc Natl Acad Sci U S A. 80(19): 59905994.

183


____________________________________________________________ References
Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, Hartley SB, Menon
S, Kastelein R, Bazan F , O’Garra A. 1997. IGIF does not drive Th1 development
but synergizes with IL-12 for interferon- production and activates IRAK and NF- B
of outstanding interest . Immunity. 7: 571–581.
Rocha B, Dautigny N, Pereira P. 1989. Peripheral T lymphocytes: expansion
potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur. J.
Immunol. 19: 905-911.
Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia
F. 1997. Selective expression of an interleukin-12 receptor component by human T
helper 1 cells. J Exp Med. 185(5): 825-831.

Rollins BJ. 1997. Chemokines. Blood. 90: 909-928.
Romagnani S. 1992. Induction of TH1 and TH2 responses: a key role for the 'natural'
immune response? Immunol Today. 13(10) :379-381. Review.
Romagnani S. 1997. The Th1/Th2 paradigm. Immunol Today. 18(6): 263-266.
Review.
Romani L, Mencacci A, Tonnetti L, Spaccapelo R, Cenci E, Puccetti P, Wolf SF,
Bistoni F. 1994. IL-12 is both required and prognostic in vivo for T helper type 1
differentiation in murine candidiasis. J Immunol. 53(11): 5167-5175.
Roos RS, Loetscher M, Legler DF, Clark-Lewis I, Baggiolini M, Moser B. 1997.
Identification of CCR8, the receptor for the human CC chemokine I-309. J Biol
Chem. 272(28): 17251-17254.
Roosnek E, Hogendijk S, Zawadynski S, Speiser D, Tiercy JM, Helg C, Chapuis
B, Gratwohl A, Gmur J, Seger R. 1993. The frequency of pretransplant donor
cytotoxic T cell precursors with anti-host specificity predicts survival of patients
transplanted with bone marrow from donors other than HLA-identical siblings.
Transplantation. 56(3): 691-696.
Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. 1992.
RANTES and macrophage inflammatory protein 1 alpha induce the migration and
activation of normal human eosinophil granulocytes. J Exp Med. 176(6): 1489-1495.
Rus V, Svetic A, Nguyen P, Gause WC, Via CS. 1995. Kinetics of Th1 and Th2
cytokine production during the early course of acute and chronic murine graft-versushost disease. Regulatory role of donor CD8+ T cells. J Immunol. 155(5): 2396-2406.
Ruscetti FW, Morgan DA and Gallo RC. 1977. Functional and morphologic
characterization of human T cells continuously grown in vitro. J Immunol. 119(1):
131-138.

184


____________________________________________________________ References
Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I.

1995. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by
an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol. 25(11):
3053-3059.
Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. 1993. Ulcerative
colitis-like disease in mice with a disrupted interleukin-2 gene.Cell. 75(2): 253-61.
Saito Y, Sabe H, Suzuki N, Kondo S, Ogura T, Shimizu A, Honjo T. 1988. A
larger number of L chains (Tac) enhance the association rate of interleukin 2 to the
high affinity site of the interleukin 2 receptor. J Exp Med. 168(5): 1563-1572.
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains
(CD25). Breakdown of a single mechanism of self-tolerance causes various
autoimmune diseases. J Immunol. 155(3): 1151-1164.
Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M,
Kuniyasu Y, Nomura T, Toda M, Takahashi T. 2001. Immunologic tolerance
maintained by CD25+ CD4+ regulatory T cells: their common role in controlling
autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 182: 1832.
Sakaguchi S. 2000. Regulatory T cells: key controllers of immunologic selftolerance. Cel.l 101: 455 –458.
Sallusto F, Lanzavecchia A and Mackay CR. 1998. Chemokines and chemokine
receptors in T-cell priming and Th1/Th2-mediated responses. Immunology Today 19:
568-574.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. 1998. Flexible programs of
chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J
Exp Med. 187(6): 875-883.
Sallusto F, Mackay CR and Lanzavecchia A. 1997. Selective expression of the
eotaxin receptor CCR3 by human T helper 2 cells. Science. 277(5334): 2005-2007.
Samson M, Stordeur P, Labbe O, Soularue P, Vassart G, Parmentier M. 1996.
Molecular cloning and chromosomal mapping of a novel human gene, ChemR1,
expressed in T lymphocytes and polymorphonuclear cells and encoding a putative
chemokine receptor. Eur J Immunol. 26(12): 3021-3028.
Santos GW. 1983. History of bone marrow transplantation. Clin Haematol. 12(3):
611-39.

Sayegh MH, Watschinger B and Carpenter CB. 1994. Mechanisms of T cell
recognition of alloantigen. The role of peptides. Transplantation. 57(9): 1295-302.
Review.

185


____________________________________________________________ References
Schmidt-Wolf IG, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S. 1992.
T-cell subsets and suppressor cells in human bone marrow. Blood. 80(12): 3242-3250.
Schwarer AP, Jiang YZ, Brookes PA, Barrett AJ, Batchelor JR, Goldman JM,
Lechler RI. 1993. Frequency of anti-recipient alloreactive helper T-cell precursors in
donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow
transplantation. Lancet. 341(8839): 203-205.
Schwarer AP, Jiang YZ, Deacock S, Brookes PA, Barrett AJ, Goldman JM,
Batchelor JR, Lechler RI. 1994. Comparison of helper and cytotoxic antirecipient T
cell frequencies in unrelated bone marrow transplantation. Transplantation. 58(11):
1198-1203.
Seder RA and Paul WE. 1994. Acquisition of lymphokine-producing phenotype by
CD4+ T cells. Annu Rev Immunol. 12: 635-673. Review.
Segall M, Noreen H, Edwins L, Haake R, Shu XO, Kersey J. 1996. Lack of
correlation of MLC reactivity with acute graft-versus-host disease and mortality in
unrelated donor bone marrow transplantation. Hum. Immunol. 49: 49-55.
Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E,
Matsushima GK, Lira SA, Cook DN, Blazar BR. 2000. T-lymphocyte production
of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T
cells to the liver, lung, and spleen during graft-versus-host disease. Blood. 96(9):
2973-2980.
Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Frelinger JA. 1999. Murine T
lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in

causing graft-versus-host disease across a class I but not class II major
histocompatibility complex barrier. Blood. 93(1): 43-50.
Shevach EM. 2000. Regulatory T cells in autoimmunity. Annu Rev Immunol. 18: 423
–449.
Shimizu J, Yamazaki S, Sakaguchi S. 1999. Induction of tumor immunity by
removing CD25+CD4+ T cells: a common basis between tumor immunity and
autoimmunity. J Immunol. 163: 5211 –5218.
Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. 2002. Stimulation of
CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance.
Nat Immunol. 3: 135 –142.

Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, Baurmann H, Schmidt CA,
Musch R, Schmid HJ, Hartmann R, Henze G, Huhn D. 1990. Soluble interleukin 2
receptors in patients after bone marrow transplantation. Bone Marrow Transplant.
6(2): 97-101.

186